136 related articles for article (PubMed ID: 23482770)
41. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
42. Correlation of neuroendocrine features with prognosis of non-small cell lung cancer.
Feng J; Sheng H; Zhu C; Qian X; Wan D; Su D; Chen X; Zhu L
Oncotarget; 2016 Nov; 7(44):71727-71736. PubMed ID: 27687592
[TBL] [Abstract][Full Text] [Related]
43. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.
Yang G; Wang XJ; Huang LJ; Zhou YA; Tian F; Zhao JB; Chen P; Liu BY; Wen MM; Li XF; Zhang ZP
PLoS One; 2015; 10(8):e0135576. PubMed ID: 26270652
[TBL] [Abstract][Full Text] [Related]
44. The roles of CD133 expression in the patients with non-small cell lung cancer.
Wang D; Wen GM; Hou W; Xia P
Cancer Biomark; 2018; 22(3):385-394. PubMed ID: 29758924
[TBL] [Abstract][Full Text] [Related]
45. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
46. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic value study of lung cancer molecular markers].
García Luján R; Conde Gallego E; López Ríos F; Martín De Nicolás JL; Sánchez Céspedes M; García Quero C; López Encuentra A
Med Clin (Barc); 2009 Apr; 132(14):529-36. PubMed ID: 19368933
[TBL] [Abstract][Full Text] [Related]
48. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
49. Correlation between survivin expression and prognosis in non-small cell lung cancer.
Atikcan S; Unsal E; Demirag F; Köksal D; Yilmaz A
Respir Med; 2006 Dec; 100(12):2220-6. PubMed ID: 16650973
[TBL] [Abstract][Full Text] [Related]
50. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer.
Hage R; Elbers HR; Brutel de la Rivière A; van den Bosch JM
Chest; 1998 Nov; 114(5):1316-20. PubMed ID: 9824008
[TBL] [Abstract][Full Text] [Related]
51. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Li J; Li ZN; Yu LC; Bao QL; Wu JR; Shi SB; Li XQ
Lung Cancer; 2010 Jul; 69(1):116-22. PubMed ID: 19875192
[TBL] [Abstract][Full Text] [Related]
52. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
53. Detection and characterization of CD133+ cancer stem cells in human solid tumours.
Tirino V; Desiderio V; d'Aquino R; De Francesco F; Pirozzi G; Graziano A; Galderisi U; Cavaliere C; De Rosa A; Papaccio G; Giordano A
PLoS One; 2008; 3(10):e3469. PubMed ID: 18941626
[TBL] [Abstract][Full Text] [Related]
54. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
[TBL] [Abstract][Full Text] [Related]
55. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Roudi R; Korourian A; Shariftabrizi A; Madjd Z
Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
[TBL] [Abstract][Full Text] [Related]
56. A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Sun J; Zhu M; Shen W; Wang C; Dai J; Xu L; Jin G; Hu Z; Ma H; Shen H
Pharmacogenomics J; 2017 Jun; 17(3):280-285. PubMed ID: 26951883
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
58. Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer.
León-Atance P; Moreno-Mata N; González-Aragoneses F; Cañizares-Carretero MÁ; Poblet-Martínez E; Genovés-Crespo M; García-Jiménez MD; Honguero-Martínez AF; Rombolá CA; Simón-Adiego CM; Peñalver-Pacual R; Alvarez-Fernández E
Arch Bronconeumol; 2012 Feb; 48(2):49-54. PubMed ID: 22153581
[TBL] [Abstract][Full Text] [Related]
59. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
